- MOTS-c is a 16-residue mitochondrial-derived peptide encoded within the 12S ribosomal RNA region of mitochondrial DNA, studied for activation of the AMPK energy-sensing pathway.
- Some rodent work reports sex differences, an unusually high share of sex-aware animal data for this database, yet no human female data exists.
- There is no menstrual cycle, pregnancy, lactation, or hormonal interaction data in humans, so the female-evidence type is honestly recorded as none.
MOTS-c has an origin story unusual among signaling peptides: it is encoded inside the mitochondrial genome itself. The 16-residue sequence sits within the 12S ribosomal RNA region of mitochondrial DNA, which makes it a mitochondrial-derived peptide rather than a product of the nuclear genome. That identity is what has made it a notable tool compound in metabolic and mitochondrial research, and it is also why it turns up in longevity catalogs.
For a site built around female physiology, MOTS-c is an interesting case because it is closer than most compounds to having sex-aware data, and still far from having human female data. Holding both of those facts at once is the honest way to describe it.
What MOTS-c is studied for
In vitro and in preclinical systems, MOTS-c has been studied for its activation of the AMPK energy-sensing pathway and its influence on glucose and lipid metabolism, along with effects on the folate cycle and metabolic-stress responses. Researchers in metabolic and exercise physiology have used it as a research material to probe how mitochondrial signals communicate with cellular energy pathways.
What makes MOTS-c notable for a metabolic and longevity catalog is its identity as a mitochondrially encoded regulator of whole-cell energetics. It is a signal that appears to run from the mitochondrion outward to cellular energy handling. Whether these mechanisms translate to people, and specifically to female physiology, remains an open research question.
The sex-difference wrinkle
Here MOTS-c is genuinely unusual for this database. In the indexed literature, some studies used female animals, and a smaller number reported sex differences in rodents. That is an unusually high share of sex-aware work for a compound at this stage, and some rodent work also suggests estrogen may modulate mitochondrial-peptide effects. None of that should be over-read. It is animal data, and the human counterpart does not exist. The honest summary is that MOTS-c has more sex-aware preclinical signal than most entries here, and zero human female data to go with it. The rodent estrogen observation is a reason to ask the question in people, not an answer to it.
Despite the sex-aware rodent work, our review records MOTS-c's female-evidence type as none, because none of the human-relevant female questions have controlled human data behind them. Animal sex differences do not upgrade the human evidence state; they only sharpen the question.
- Menstrual cycle interactions: no data.
- Pregnancy and lactation: no safety data.
- Hormonal interactions: rodent work hints estrogen may modulate effects, but this is uncharacterized in humans.
- Perimenopause and menopause: no data in these populations.
- Sex differences: reported in some rodent studies; no human female data exists.
On dose, MOTS-c figures are reported in animal studies only, with no established human dose. We note that only as a description of where the research stands.
This site does not publish personal dosing. Animal-study figures describe the research record for context; they are not a protocol, a human dose, or medical advice.
MOTS-c is a good illustration of why the female-evidence lens is tri-state rather than a checkbox. It has more sex-aware animal data than almost anything else in the catalog, and it still lands at an honest none for human female evidence. Both facts belong in the record. The structured review sits on the compound profile at MOTS-c.